LogoLogoMSF Science Portal
  • My saved items
logo

© Médecins Sans Frontières

MSF Science Portal
About MSF Science Portal
About MSF
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use

v2.1.4829.produseast1

Journal Article > Review

New and repurposed drugs for pediatric multidrug-resistant tuberculosis. Practice-based recommendations

Harausz EP, Garcia-Prats AJ, Seddon JA, Schaaf HS, Hesseling AC, Achar J, Bernheimer J, Cruz AT, DAmbrosio L, Detjen AK, Graham SM, Hughes J, Jonckheere S, Marais BJ, Battista Migliori G, McKenna L, Skrahina A, Tadolini M, Wilson P, Furin J, Sentinel Project on Pediatric Drug-Resistant TB
Download
Download
Abstract
It is estimated that 33,000 children develop multidrug-resistant tuberculosis (MDR-TB) each year. In spite of these numbers, children and adolescents have limited access to the new and repurposed MDR-TB drugs. There is also little clinical guidance for the use of these drugs and for the shorter MDR-TB regimen in the pediatric population. This is despite the fact that these drugs and regimens are associated with improved interim outcomes and acceptable safety profiles in adults. This review fills a gap in the pediatric MDR-TB literature by providing practice-based recommendations for the use of the new (delamanid and bedaquiline) and repurposed (linezolid and clofazimine) MDR-TB drugs and the new shorter MDR-TB regimen in children and adolescents.
Subject Area
tuberculosispediatricsantimicrobial resistance
DOI
10.1164/rccm.201606-1227CI
Published Date
17-Nov-2016
PubMed ID
27854508
Languages
English
Journal
American Journal of Respiratory and Critical Care Medicine
Volume / Issue / Pages
Volume 195, Issue 101, Pages 1300-1310
Dimensions Badge